RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested to fight tough head and neck cancers
Disease control OngoingThis study is testing whether combining two existing drugs, pembrolizumab and cabozantinib, can help control advanced head and neck cancer that has come back or spread. It will involve about 36 patients whose cancer cannot be removed by surgery. The main goal is to see how many p…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug cocktail aims to stall aggressive head and neck cancers
Disease control OngoingThis study tested whether adding the drug sorafenib to two standard chemotherapy drugs (carboplatin and paclitaxel) could better control advanced head and neck cancer that has returned or spread. It involved 48 patients with this difficult-to-treat cancer. The main goal was to se…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to tame tough head and neck cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug (cemiplimab) with two low-dose chemotherapy drugs works better for treating head and neck cancer that has returned or spread. It will involve about 46 patients whose cancer has come back or spread and who haven't had o…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC